
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its financial results for the second quarter of 2006.
Waltham, MA – July 27, 2006 – Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its financial results for the second quarter of 2006.
Revenues for the second quarter of 2006 were $24.7 million, a 19% increase from $20.7 million in the second quarter of 2005. Within total revenue, InForm™ license, application hosting and other related revenues were $16.3 million, an increase of 19% from $13.7 million in the prior year period.






